Summit Therapeutics Inc. 8-K

What Happened
Summit Therapeutics Inc. announced its financial results and operational progress for the fourth quarter and full year ended December 31, 2025 via a press release dated February 23, 2026. The company also scheduled an earnings call for 4:30 p.m. ET on February 23, 2026 and will use a slide presentation during that call to summarize results and provide an operational update.

Key Details

• Press release announcing Q4 and full-year 2025 results issued on February 23, 2026 (furnished as Exhibit 99.1 to the 8-K).
• Earnings call scheduled for 4:30 p.m. ET on February 23, 2026; slide deck for the call furnished as Exhibit 99.2.
• Reporting period covered: fourth quarter and full year ended December 31, 2025.
• Form 8-K signed by Manmeet S. Soni (Chief Operating Officer, Chief Financial Officer and Director) on February 23, 2026.

Why It Matters
This filing delivers Summit’s latest earnings and operational update that investors use to evaluate revenue, cash position, R&D progress and near-term plans. The press release and slide deck are the primary sources for the specific financial figures and business updates; investors should review those materials and listen to the earnings call for detailed results and management commentary.